BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Trial for patients with refractory multiple myeloma after failure of at least two treatment
regimens and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors
Encorafenib (LGX818 in) combination with Binimetinib (MEK162).
Phase:
Phase 2
Details
Lead Sponsor:
University of Heidelberg Medical Center
Collaborators:
Array BioPharma Coordinating Centre for Clinical Trials Heidelberg German Cancer Research Center University Hospital Heidelberg